Default company panoramic image

Precipio Diagnostics, LLC

Precipio harnesses the intellect, expertise, and technology developed within academia, and delivers it to community physicians.

  • Stage $500K in TTM Revenue
  • Industry Healthcare Services
  • Location New Haven, CT, USA
  • Currency USD
  • Founded September 2011
  • Employees 14
  • Website

Company Summary

Precipio partners with academic institutions to bring the highest standard of pathology & diagnostics to community oncologists. Our customers are oncologists, who are entirely reliant on pathology to guide them in treating their patients. We take the expertise, technology, & intellectual capital often locked up within academia, and after adding the proper processes and service level, deliver it to physicians, improving patient care.


  • Default avatar
    Ilan Danieli

    Ilan has 15+ years of senior management and operational experience built on strong people skills, and common sense. Previous experiences includes CEO of a cancer diagnostics lab, COO of a $100M multi-national public company, and VP of Operations at a multi-billion dollar hedge fund. Working in both entrepreneurial, and public company operations, Ilan understands people, operations, sales, marketing, finance & legal - and their inter-dependence.

  • Default avatar
    Gil Alon

    Gil is a seasoned finance executive, with over 15 years of experience in financing start-up and health care institutions, as well as corporate turnarounds and restructurings at private equity fund. Holds an MBA from NYU and BA from UCLA.

  • Default avatar
    Demetrios Braddock, MD, Ph.D
    Medical Director

    Dr. Braddock received his MD/PhD degree from the University of Chicago, was trained in Anatomic Pathology at the NIH, and has been on the faculty of Yale since 2004 where his primary clinical focus is Hematopathology. He is currently an Associate Professor of Pathology at Yale, where he directs an independent laboratory focused on the structural elucidation of proteins and protein complexes that drive hematopoietic disorders.

  • Default avatar
    Jeffrey Sklar, MD, Ph.D
    Chief Scientific Officer

    Dr. Sklar is a tenured faculty at Yale University. He holds a BA from Haverford College, an MD and Ph.D. from Yale University, a Post-doctorate fellowship in Biochemistry at Stanford University, and a MA from Harvard University. Dr. Sklar is a pioneer and one of the world leading thinkers in the area of molecular genetics. He has developed several tests that are standard protocol of testing within pathology diagnostics laboratories.

  • Default avatar
    David Hudnall, MD
    Associate Medical Director

    S. David Hudnall is Professor of Pathology and Laboratory Medicine, and Director of Hematopathology at Yale University School of Medicine. Dr. Hudnall attended medical school at the Medical University of South Carolina in Charleston, SC (1974-78). Following his medical training, Dr. Hudnall completed his residency in Anatomic and Clinical Pathology at the Yale-New Haven Hospital, Yale University School of Medicine (1978-82). This training was fol


  • Default avatar
    Goodwin Proctor
    Default avatar
    Teplitzky & Company

Previous Investors

  • Default avatar
    Kuzari Capital
    Default avatar
    Friends & Family investors